GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Apnimed, Inc. Common Stock APMD · USD

US listing · 🇺🇸 United States

Compare

15.81

+4.70%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Apnimed, Inc. Common Stock

Its shares trade under the ticker APMD. It has been listed since 31 July 2026. In the fiscal year to 31 December 2025, it reported revenue of $38.5m and a net loss of $932,000. At that date it held total assets of $72.9m and shareholders' equity of −$372.8m.

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Listed since
31 Jul 2026
Website
apnimed.com ↗
Head office
39 JOHN F. KENNEDY STREET, 4TH FLR., CAMBRIDGE, MA, 02138
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Operates as a clinical pharmaceutical company developing novel oral therapies for sleep-related breathing diseases.
  • Products include AD109, an oral therapy targeting neuromuscular dysfunction for obstructive sleep apnea.
  • Incorporated in 2017 with headquarters in Cambridge, Massachusetts.

Weaknesses

  • Sector and industry are listed as unknown in the provided information.
  • IPO date is set for 2026-07-31, indicating no current public trading status.
  • Website source description is marked as untrusted, potentially affecting credibility.

Opportunities

  • Global market potential for novel oral therapies addressing sleep-related breathing diseases.
  • AD109 targets the underlying neuromuscular dysfunction of obstructive sleep apnea, a significant health issue.
  • Incorporation year 2017 suggests a relatively established company structure for a clinical pharmaceutical firm.

Threats

  • Unspecified sector and industry may hinder market positioning and investor understanding.
  • IPO in 2026-07-31 suggests potential delays or challenges in reaching public markets.
  • Untrusted source description could lead to skepticism about company claims and product efficacy.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.